Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
Revvity, Inc. said it is developing the T-SPOT A201, a next-generation high-throughput automated platform for latent TB testing. The company targets a second-half 2027 launch, aiming to match T-SPOT.TB performance while improving workflow efficiency and scalability for large labs. Revvity shares rose 2.4% after the announcement.
How this was made
The 30-second read
Why it matters
If commercialized successfully, the platform could broaden access to T-SPOT.TB benefits for high-volume labs by increasing throughput and reducing hands-on time, supporting longer-term customer relationships.
Market read
A new automation platform with quantified throughput and hands-on time targets could improve the economics of latent TB testing for high-volume labs, but financial impact is not quantified yet.
What to watch
Key risks are execution and adoption timing: instrument qualification, reimbursement dynamics, and whether labs standardize on Revvity versus competing automation platforms before 2H 2027.
Background
Revvity already offers the Auto-Pure 2400 liquid handler for lower-volume T-SPOT.TB workflows; T-SPOT A201 is positioned as the high-throughput next step.
Ticker impact
Revvity announced the T-SPOT A201 next-generation automated platform for high-throughput latent TB testing, targeting launch in 2H 2027.
Near-term impact likely limited to sentiment, with more meaningful repricing dependent on commercialization milestones and customer uptake.
The article provides product specs and a launch window but no financial guidance, regulatory decision, or signed commercial orders, so the decision value is moderate.
Market effects
Supports the broader lab automation and infectious disease diagnostics theme, reinforcing demand drivers for scalable TB testing workflows.
Emphasizes U.S. TB testing demand drivers (immigration screening, public health initiatives), which may benefit domestic lab automation spend.
Latent TB screening is a global public health need, so automation capacity expansion could influence international procurement cycles over time.
Counterpoint
Without commercialization traction, the market may treat the T-SPOT A201 as a long-dated roadmap item rather than a near-term revenue catalyst.
Key entities
- companyRevvity, Inc.
Developer of the T-SPOT A201 high-throughput automated platform for latent TB testing.
- productT-SPOT A201
Next-generation automated platform designed to scale T-SPOT.TB workflows for large clinical laboratories.
- diagnostic_assayT-SPOT.TB
Latent tuberculosis testing assay whose workflow the A201 is designed to automate at higher throughput.
